These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24801834)

  • 1. Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer.
    Ward-Kavanagh LK; Zhu J; Cooper TK; Schell TD
    Cancer Immunol Res; 2014 Aug; 2(8):777-88. PubMed ID: 24801834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.
    Cozza EM; Cooper TK; Budgeon LR; Christensen ND; Schell TD
    Cancer Immunol Immunother; 2015 Mar; 64(3):325-36. PubMed ID: 25408469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer.
    Jenq RR; Curran MA; Goldberg GL; Liu C; Allison JP; van den Brink MR
    PLoS One; 2012; 7(4):e35222. PubMed ID: 22493742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors.
    Ward-Kavanagh LK; Kokolus KM; Cooper TK; Lukacher AE; Schell TD
    Cancer Immunol Immunother; 2018 Apr; 67(4):639-652. PubMed ID: 29332158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.
    Shafer-Weaver KA; Watkins SK; Anderson MJ; Draper LJ; Malyguine A; Alvord WG; Greenberg NM; Hurwitz AA
    Cancer Res; 2009 Aug; 69(15):6256-64. PubMed ID: 19622771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer.
    Chou CK; Schietinger A; Liggitt HD; Tan X; Funk S; Freeman GJ; Ratliff TL; Greenberg NM; Greenberg PD
    J Immunol; 2012 Oct; 189(8):3936-46. PubMed ID: 22984076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.
    Ryan CM; Staveley-O'Carroll K; Schell TD
    J Immunother; 2008; 31(9):906-20. PubMed ID: 18832997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression.
    Diener KR; Woods AE; Manavis J; Brown MP; Hayball JD
    Lab Invest; 2009 Feb; 89(2):142-51. PubMed ID: 19079323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
    Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.
    Klyushnenkova EN; Kouiavskaia DV; Parkins CJ; Caposio P; Botto S; Alexander RB; Jarvis MA
    J Immunother; 2012 Jun; 35(5):390-9. PubMed ID: 22576344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
    Ma J; Wang YL; Hu HM; Fox BA; Si LS
    Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.
    Bak SP; Barnkob MS; Wittrup KD; Chen J
    Cancer Immunol Res; 2013 Dec; 1(6):393-401. PubMed ID: 24778132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.
    Bai A; Higham E; Eisen HN; Wittrup KD; Chen J
    Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13003-8. PubMed ID: 18723683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.
    Wada S; Yoshimura K; Hipkiss EL; Harris TJ; Yen HR; Goldberg MV; Grosso JF; Getnet D; Demarzo AM; Netto GJ; Anders R; Pardoll DM; Drake CG
    Cancer Res; 2009 May; 69(10):4309-18. PubMed ID: 19435909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells.
    Kjaergaard J; Peng L; Cohen PA; Shu S
    Clin Immunol; 2003 Jul; 108(1):8-20. PubMed ID: 12865066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors.
    Plautz GE; Inoue M; Shu S
    Cell Immunol; 1996 Aug; 171(2):277-84. PubMed ID: 8806798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy.
    Ciavarra RP; Holterman DA; Brown RR; Mangiotti P; Yousefieh N; Wright GL; Schellhammer PF; Glass WF; Somers KD
    J Immunother; 2004; 27(1):13-26. PubMed ID: 14676630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer.
    Liu Z; Eltoum IE; Guo B; Beck BH; Cloud GA; Lopez RD
    J Immunol; 2008 May; 180(9):6044-53. PubMed ID: 18424725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.
    Kodumudi KN; Weber A; Sarnaik AA; Pilon-Thomas S
    J Immunol; 2012 Dec; 189(11):5147-54. PubMed ID: 23100512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
    Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
    J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.